News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.
In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.
Pivoting from a technology that it deemed wasn't robust enough, Confer Health is now designing a platform to enable broad-scale testing at home.
The firm hopes the effort, recently described in the journal Oncotarget, will spur adoption of its testing services by oncologists, particularly in Europe, where it is determined to become a market leader.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
